- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05629689 | A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies | terminated | Phase 1 | 19 | GE HealthcareINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT00801151 | Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer | terminated | Phase 1 | 30 | Institut Claudius RegaudOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06573294 |
| Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors |
| terminated |
| Phase 1 |
| 23 |
| GenmabINDUSTRY |
| 3 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT05101213 | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | terminated | Phase 1 / Phase 2 | 21 | GenmabINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | terminated | Phase 1 / Phase 2 | 3 | Tianhong LiOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT04379518 | Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05859464 | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 34 | Zai Lab (Hong Kong), Ltd.INDUSTRY | 3 | Oct 20, 2025 | clinicaltrials |
| NCT01309490 | Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Jewish General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06630247 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 9 | ExelixisINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05135650 | Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study | terminated | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05098405 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | terminated | Phase 1 | 46 | Molecular Partners AGINDUSTRY | 2 | Jan 30, 2025 | clinicaltrials |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | terminated | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04060849 | Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY | terminated | Phase 1 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04168320 | SBRT-based PArtial Tumor Irradiation of HYpoxic Segment(SBRT-PATHY) | terminated | Phase 1 | 30 | Klinikum Klagenfurt am WörtherseeOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04729725 | SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03884517 | Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer | terminated | Phase 1 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 28, 2023 | clinicaltrials |
| NCT04800627 | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | terminated | Phase 1 / Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02801097 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)(PAYLOAD) | terminated | Phase 1 | 28 | EpicentRx, Inc.INDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT03254732 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | terminated | Phase 1 | 33 | Polaris GroupINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | terminated | Phase 1 / Phase 2 | 7 | Oncovir, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | terminated | Phase 1 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00977067 | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 0 | Jun 21, 2017 | clinicaltrials |
| NCT02096341 | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | terminated | Phase 1 | 23 | Yale UniversityOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT01416623 | A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 44 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2012 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials